Literature DB >> 28994418

PTPN2: a tumor suppressor you want deleted?

Florian Wiede1, Tony Tiganis1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28994418     DOI： 10.1038/icb.2017.70

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


× No keyword cloud information.
  19 in total

Review 1.  FDA-approved small-molecule kinase inhibitors.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Trends Pharmacol Sci       Date:  2015-05-12       Impact factor: 14.819

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 3.  Protein tyrosine phosphatase function: the substrate perspective.

Authors:  Tony Tiganis; Anton M Bennett
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

4.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Authors:  Robert T Manguso; Hans W Pope; Margaret D Zimmer; Flavian D Brown; Kathleen B Yates; Brian C Miller; Natalie B Collins; Kevin Bi; Martin W LaFleur; Vikram R Juneja; Sarah A Weiss; Jennifer Lo; David E Fisher; Diana Miao; Eliezer Van Allen; David E Root; Arlene H Sharpe; John G Doench; W Nicholas Haining
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

Review 5.  SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.

Authors:  Ulrike Lorenz
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

6.  PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity.

Authors:  Florian Wiede; Faruk Sacirbegovic; Yew Ann Leong; Di Yu; Tony Tiganis
Journal:  J Autoimmun       Date:  2016-09-19       Impact factor: 7.094

7.  Sticking It to Cancer with Molecular Glue for SHP2.

Authors:  Hao Ran; Ryouhei Tsutsumi; Toshiyuki Araki; Benjamin G Neel
Journal:  Cancer Cell       Date:  2016-08-08       Impact factor: 31.743

Review 8.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Authors:  Peter Savas; Roberto Salgado; Carsten Denkert; Christos Sotiriou; Phillip K Darcy; Mark J Smyth; Sherene Loi
Journal:  Nat Rev Clin Oncol       Date:  2015-12-15       Impact factor: 66.675

9.  PTPN2 regulates T cell lineage commitment and αβ versus γδ specification.

Authors:  Florian Wiede; Jarrod A Dudakov; Kun-Hui Lu; Garron T Dodd; Tariq Butt; Dale I Godfrey; Andreas Strasser; Richard L Boyd; Tony Tiganis
Journal:  J Exp Med       Date:  2017-08-10       Impact factor: 14.307

10.  Targeted disruption of TC-PTP in the proliferative compartment augments STAT3 and AKT signaling and skin tumor development.

Authors:  Hyunseung Lee; Mihwa Kim; Minwoo Baek; Liza D Morales; Ik-Soon Jang; Thomas J Slaga; John DiGiovanni; Dae Joon Kim
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379
View more
  4 in total

1.  PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.

Authors:  Florian Wiede; Kun-Hui Lu; Xin Du; Shuwei Liang; Katharina Hochheiser; Garron T Dodd; Pei K Goh; Conor Kearney; Deborah Meyran; Paul A Beavis; Melissa A Henderson; Simone L Park; Jason Waithman; Sheng Zhang; Zhong-Yin Zhang; Jane Oliaro; Thomas Gebhardt; Phillip K Darcy; Tony Tiganis
Journal:  EMBO J       Date:  2019-12-05       Impact factor: 11.598

2.  PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and Metastasis.

Authors:  Wenbin Kuang; Xiao Wang; Jiayu Ding; Jiaxing Li; Minghui Ji; Weijiao Chen; Liping Wang; Peng Yang
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

3.  Macrophage Membrane-Camouflaged shRNA and Doxorubicin: A pH-Dependent Release System for Melanoma Chemo-Immunotherapy.

Authors:  Chengli Yang; Yang Ming; Kai Zhou; Ying Hao; Danrong Hu; Bingyang Chu; Xinlong He; Yun Yang; Zhiyong Qian
Journal:  Research (Wash D C)       Date:  2022-02-08

4.  Programmable Unlocking Nano-Matryoshka-CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune Response.

Authors:  Jin Yang; Zhike Li; Meiling Shen; Yan Wang; Li Wang; Jiamiao Li; Wen Yang; Jie Li; Haijun Li; Xinxin Wang; Qinjie Wu; Changyang Gong
Journal:  Adv Sci (Weinh)       Date:  2021-05-14       Impact factor: 16.806
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.